Novo Nordisk shifts focus to oral weight-loss drugs amid GLP-1 competition

Novo Nordisk, maker of Ozempic and Wegovy, is pivoting its R&D and commercial strategy toward oral formulations of its GLP-1 drugs. This marks a strategic response to rising competition in the weight-loss market, particularly from oral alternatives. The move could reshape the obesity treatment landscape and impact Novo's market position.